Chicago Capital LLC Sells 6,529 Shares of Johnson & Johnson $JNJ

Chicago Capital LLC cut its position in Johnson & Johnson (NYSE:JNJ) by 10.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 58,983 shares of the company’s stock after selling 6,529 shares during the period. Chicago Capital LLC’s holdings in Johnson & Johnson were worth $10,937,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Worth Financial Advisory Group LLC acquired a new position in shares of Johnson & Johnson during the third quarter worth approximately $295,000. Mcdaniel Terry & Co. increased its stake in Johnson & Johnson by 0.3% during the 3rd quarter. Mcdaniel Terry & Co. now owns 192,219 shares of the company’s stock valued at $35,641,000 after purchasing an additional 550 shares in the last quarter. Brickley Wealth Management acquired a new position in Johnson & Johnson during the third quarter worth $258,000. Financial Perspectives Inc lifted its stake in shares of Johnson & Johnson by 3.1% in the third quarter. Financial Perspectives Inc now owns 8,108 shares of the company’s stock valued at $1,503,000 after buying an additional 243 shares in the last quarter. Finally, Granite Harbor Advisors Inc. grew its holdings in shares of Johnson & Johnson by 12.3% during the third quarter. Granite Harbor Advisors Inc. now owns 11,600 shares of the company’s stock valued at $2,151,000 after buying an additional 1,266 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Nipocalimab phase II success — JNJ reported nipocalimab met key endpoints in a Phase IIb SLE study, supporting a planned move to Phase III and de‑risking a late‑stage autoimmune program that could add future revenue. JNJ’s Nipocalimab Meets Goal in Phase II Study for Systemic Lupus
• Positive Sentiment: MedTech growth catalyst — J&J MedTech submitted its Ottava surgical robot to the FDA, advancing a high‑margin growth avenue in robotics/surgery that could expand addressable market if cleared. Johnson & Johnson MedTech submits Ottava surgical robot to FDA
• Positive Sentiment: Research collaboration in cardiac gene therapy — JNJ is partnering with Lexeo Therapeutics to test localized AAV delivery using Impella technology, which could accelerate novel cardiac programs and strengthen cardiovascular R&D capabilities. Lexeo Therapeutics Announces Research Collaboration with Johnson & Johnson to Advance Cardiac Gene Therapy Using Impella Technology
• Positive Sentiment: Analyst and media support — Barclays raised its JNJ price target (to $217) and Wolfe Research lifted its target to $240; high‑profile bullish commentary (Jim Cramer called it a “terrific entry point”) may attract buyers. Barclays Raises Johnson & Johnson (JNJ) Target on Strength in Key Drugs Wolfe Research Increases Johnson & Johnson Price Target to $240.00 Jim Cramer on Johnson & Johnson: “I Think It’s a Terrific Entry Point”
• Neutral Sentiment: Innovative Medicines resilience — analysts note J&J’s Innovative Medicines segment remains resilient with key drugs offsetting some pressures; watch Q4 details for cadence and guidance. J&J’s Innovative Medicine Segment in Q4: Here’s What to Watch
• Neutral Sentiment: Macro tailwind for health care — sector rotation into health-care and dividend/value themes is supportive of JNJ stock but is a broader factor rather than company‑specific. Experts See Health Care’s Rally Continuing. This ETF Is Proof
• Negative Sentiment: Commercial headwinds — continued pressure from Stelara biosimilars and Medicare Part D dynamics could weigh on sales and near‑term margins in immunology/dermatology franchises. J&J’s Innovative Medicine Segment in Q4: Here’s What to Watch

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the stock. BMO Capital Markets reaffirmed an “outperform” rating on shares of Johnson & Johnson in a research report on Thursday, December 11th. Loop Capital set a $190.00 target price on Johnson & Johnson in a report on Wednesday, October 22nd. Wells Fargo & Company lifted their target price on Johnson & Johnson from $212.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, December 12th. Weiss Ratings reissued a “buy (b)” rating on shares of Johnson & Johnson in a research report on Friday, October 31st. Finally, Morgan Stanley lifted their price objective on shares of Johnson & Johnson from $190.00 to $197.00 and gave the stock an “equal weight” rating in a report on Friday, December 12th. Four analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $212.62.

Johnson & Johnson Price Performance

JNJ opened at $205.78 on Friday. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $215.18. The firm has a 50-day moving average of $202.56 and a 200 day moving average of $184.15. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The firm has a market cap of $495.79 billion, a P/E ratio of 19.86, a PEG ratio of 2.13 and a beta of 0.34.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. The firm had revenue of $24.02 billion for the quarter. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. On average, research analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date of this dividend is Tuesday, February 24th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.